Nasdaq GlobeNewswire

Cloudbeds Raises 9 Million in Series B Funding, Led by PeakSpan Capital

Del

SAN DIEGO, June 22, 2017 (GLOBE NEWSWIRE) -- Cloudbeds, a leading provider of hospitality management software for independent properties (hotels, hostels, inns, beds and breakfasts, campgrounds, vacation rentals, and more), today announced it has completed an oversubscribed $9+ million Series B financing round.  Cloudbeds' first institutional round was led by PeakSpan Capital, and includes additional investment from Nashville Capital, Cultivation Capital, ClearVision Equity, and TTCER Partners.  The financing follows last year's Series A round of $3.14 million, bringing the total investment to date to $20 million.

"Cloudbeds brings the latest innovations in software to the hospitality industry - they are laser focused on championing the needs of independent hoteliers and setting the standard for a fully integrated, best-in-class platform," said Phil Dur, Managing Partner and Co-Founder at PeakSpan Capital. Matt Melymuka, Vice President and Co-Founder of PeakSpan added, "Great things happen when you combine focus with a truly visionary and excellent management team. We feel fortunate to lead this investment round and are looking forward to helping the company capitalize on its progress to date."

Founded in late 2012, Cloudbeds now has 102 employees worldwide with offices in San Diego, São Paulo, and Dublin. Their software now services tens of thousands of properties in 120+ countries.

Cloudbeds develops software that is designed to help independent property owners and operators become more competitive by offering an integrated system that includes property management, channel management, and a commission-free booking engine.  By offering everything in one software suite, Cloudbeds helps properties maximize occupancy while minimizing time spent on administrative tasks. In turn, this gives their clients more time to spend with their guests. In addition to offering a full software suite, the Cloudbeds channel manager, myallocator, is one of the most popular standalone channel management solutions and is used by thousands of properties. 

"We have experienced incredible success over the last few years. Cloudbeds software is used by everyone, from boutique hotels to adventure hostels, in every part of the world. We are fueling the growth of travel businesses worldwide and helping millions of people experience all the world has to offer," said Adam Harris, CEO of Cloudbeds. "We're thrilled to have PeakSpan on board with us. As investors, PeakSpan has an incredible track record of building successful companies, and their insights will be especially helpful during our next phase of growth. PeakSpan and Cloudbeds share similar cultures and values - we both believe in building highly customer-centric companies, obsessing over product, and prioritizing company culture."

"We continually strive to build a better platform and we are excited that this new round of fundraising will also help us accelerate the release of new functionality," added Richard Castle, President and COO of Cloudbeds.  "Our platform enables small lodging professionals to reach a global audience and we are looking forward to giving them more tools to help them successfully compete on a global scale."

About Cloudbeds 
Cloudbeds creates cloud-based hospitality management software that simplifies the working lives of independent property owners, operators, and employees. Cloudbeds' award-winning software is trusted by thousands of hotels, hostels, and groups in over 120 countries. With over 300 integrations, Cloudbeds connects to more marketplaces than any software in the hospitality industry. Cloudbeds has offices in San Diego, São Paulo, and Dublin. For more information, please visit www.cloudbeds.com.

About PeakSpan
PeakSpan Capital is a growth equity firm based in New York City and Silicon Valley, with a focused mission to be the partner of choice for growth stage entrepreneurial teams who are building amazing software targeted at business buyers of all sizes -- from very small businesses to large enterprises. PeakSpan combines deep domain expertise within a select number of themes with a homegrown, proprietary technology platform providing visibility into company and market performance, to help entrepreneurs drive resilient, risk-adjusted value creation. To learn more about PeakSpan Capital and its portfolio, please visit: www.peakspancapital.com.

Contact: 
Alex Gaggioli 
Marketing Manager 
alex.gaggioli@cloudbeds.com 
2655 4th Ave. San Diego, CA 92103 
+1-630-815-2124




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cloudbeds via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 201817.7.2018 22:30Pressemelding

LYON, France and CAMBRIDGE, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018. At the meeting, all resolutions for which management recommended a vote in favor, were adopted, including: - Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2017 and quietus of directors; - Allocation of the financial year's results; - Approval of regulatory agreements and commitments referred to in Article L.225-38 of the French Commercial Code; - Approval of the regulations of the share subscription and/or purchase options plan adopted by the Board of Directors on June 27, 2017; - Authorization for the Board of Directors to grant share subscription and/or share purchase options and/or to issue detachable share subscription warrants to corporate officers and employees of the Company or companies in the ERYTECH Pharma

Williams Scotsman Receives Competition Bureau Clearance for ModSpace Acquisition17.7.2018 22:15Pressemelding

BALTIMORE, July 17, 2018 (GLOBE NEWSWIRE) -- WillScot Corporation (NASDAQ:WSC) ("Williams Scotsman"), a specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that, on July 16, 2018, the Canadian Competition Bureau issued a No Action Letter relating to Williams Scotsman's proposed acquisition of Modular Space Corporation ("ModSpace"). WillScot has now obtained the regulatory approvals required to complete the acquisition and continues to progress towards closing in the third quarter of 2018. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the Williams Scotsman family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol "WSC." Williams Scotsman is a specialty rental services market leader providing innovative modular space and portable storage solutio

Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors17.7.2018 22:05Pressemelding

WALTHAM, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the election of Jeryl Hilleman to the Board of Directors of the Company. "Jeri brings a broad life sciences background to Minerva that includes high growth commercial biopharma, med-tech and data science companies," said William F. Doyle, Lead Independent Director of Minerva. "Her track record of delivering strategic and financial growth through execution, strategic partnering and multiple acquisitions will serve Minerva well as the Company completes five ongoing late-stage clinical trials with roluperidone, seltorexant and MIN-117." Ms. Hilleman is presently Chief Financial Officer of Intersect ENT (NASDAQ:XENT), a medical device company with commercial products for the treatment of chronic sinusitis. Previously, she served as CFO of several public

Orion Biotechnology Awarded a $2M Grant from National Center for Research and Development to Fund Further Development of its HIV Microbicide17.7.2018 21:00Pressemelding

OTTAWA, July 17, 2018 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that its European subsidiary, Orion Biotechnology Polska Sp. z o.o., was awarded a grant of $2M US dollars by the National Center for Research and Development . The grant will fund a project to advance development of the company's innovative microbicide candidate (OB-002H). Designed to prevent the transmission of HIV, OB-002H has the potential to address an urgent and growing need for an HIV prevention product that is affordable, appealing to use, and easily integrates into the lifestyles of people at risk for HIV infection regardless of age, sex or gender. The project is co-financed by the National Center for Research and Development under the InnoNeuroPharm program - Measure 1.2: Sectoral R & D programs of the Intelligent Development Operational Program 2014-2020. Orion Biotechnology will use the grant to complete IND enabling studies, advance OB-002H to

Greater Anglia Selects PowerPlan to Optimise Its Asset Investments17.7.2018 15:29Pressemelding

ATLANTA, July 17, 2018 (GLOBE NEWSWIRE) -- Greater Anglia, a UK-based train operating company, has selected PowerPlan's Asset Investment Optimization software suite to maximise its asset investments over a 40-year time period. Greater Anglia's long-term investment strategy includes a 40-year asset plan to meet its regulatory requirements. For what was historically built with manual processes and not easily tracked, the Asset Investment Optimization solution from PowerPlan will provide a comprehensive, auditable approach to help the company analyze different investment scenarios for impacts to risk, cost, timing and level of service and provide a defendable asset plan for the next four decades. "The condition of our assets drives our business," said Richard Turner, Head of Asset Management for Greater Anglia. "With PowerPlan, we can apply a fact-based methodology to prioritise investments, maximise their return and produce plans that communicate our asset strategy to internal and extern

Oxford Immunotec Schedules Second Quarter 2018 Earnings Release and Conference Call for July 31, 201817.7.2018 14:30Pressemelding

OXFORD, United Kingdom and MARLBOROUGH, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it plans to release second quarter 2018 financial results prior to market open on Tuesday, July 31, 2018. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 9268558, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom